Individualized tumor therapeutic vaccine and preparation method thereof

Abstract

The invention relates to the field of biological medicines, and provides an individualized tumor therapeutic vaccine and a preparation method thereof in order to improve the individualized treatment effect of tumor patients. An individualized tumor neoantigen group is obtained by comparing tumor tissues and normal tissues of a subject, a tumor neoantigen peptide group is synthesized, and the tumor neoantigen peptide group and adjuvants are used for preparing the anti-tumor vaccine, wherein the adjuvants comprise Poly (IC: LC) and STING agonists. The adjuvants composed of Poly (IC: LC) and STING agonists can effectively activate an organism to generate CD4 + cellular immune response and CD8 + cellular immune response of a tumor neoantigen peptide group which aims at abnormal expression of tumors and is composed of MHC class I restrictive epitope peptides and MHC class II restrictive epitope peptides, so that tumor growth is remarkably inhibited, and no obvious adverse reaction is generated.

Description

technical field [0001] The invention belongs to the field of biomedicine, in particular to an individualized tumor therapeutic vaccine and a preparation method thereof, in particular to a tumor neoantigen epitope peptide combined with Poly(IC:LC) and an interferon gene stimulating protein STING agonist in anti-tumor in the application. Background technique [0002] Malignant tumor is a major disease that threatens human health, and its incidence is increasing year by year, which is a major challenge in the current medical research field. In recent years, breakthroughs have been made in the research of tumor immunotherapy. There are various forms of tumor immunotherapy, including tumor targeting antibodies, immune system regulating antibodies, tumor vaccines, adoptive immune cell therapy, etc. [0003] Therapeutic vaccines have a history of more than 200 years since their birth. Although they cannot completely replace drugs, they have become an auxiliary means of disease tr...

AI Technical Summary

Problems solved by technology

[0006] In addition, due to the diversity of tumor pathogenesis and clinical manifestations, even tumors belonging to the same type clinically have huge differences among different patients. The shortcoming of unstable therapeutic effect of vaccines is manifested in the fact that the curative effect of tumor therapeutic vaccines is good in a very small number of individuals, but in most cases the curative effect is poor or even completely ineffective, which seriously hinders the technical development and application of tumor therapeutic vaccines

[0007] In order to solve the problems of poor immunogenicity and unstable effect of tumor therapeutic vaccines, existing technologies mainly focus on finding new tumor-specific peptides with strong immunogenicity and transforming existing tumor-associated peptides (for example, by linking carriers, structural modification, Fusion expression, molecular simulation, etc.), combined use of multiple tumor-associated peptides, addition of adjuvants, etc.

However, the above-mentioned technical route cannot fundamentally solve the technical problem. Instead, the introduction of more immunogens dilutes the effect of effective immunogens. At the same time, the introduction of more ineffective immunogens and adjuvants also brings higher security risks.

Images